MoonLake Immunotherapeutics has recently released its 10-Q report. The company is a clinical-stage biotechnology firm focused on therapies for inflammatory skin and joint diseases. Its lead program is sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody being developed across several inflammatory indications, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis and psoriasis. Founded in 2021 and based in Zug, Switzerland, MoonLake is still in the development stage and has not yet brought a product to market.
In Item 2, Management’s Discussion and Analysis, MoonLake says the quarterly discussion should be read alongside its unaudited condensed consolidated financial statements for the three months ended March 31, 2026 and its audited 2025 annual financial statements filed in February 2026. The company states that the March 31, 2026 interim statements were prepared under U.S. GAAP and presented in U.S. dollars. It also clarifies that references to “MoonLake,” “we,” “us,” “our,” “our Company,” “the Company” and “our business” mean MoonLake Immunotherapeutics and its consolidated subsidiaries. As a result of these announcements, the company's shares have moved 8.29% on the market, and are now trading at a price of $18.475. Check out the company's full 10-Q submission here.
